A. Kazantsev

发表

Therapeutic application of histone deacetylase inhibitors for central nervous system disorders

L. Thompson, A. Kazantsev, 2008, Nature Reviews Drug Discovery.

The first 17 amino acids of Huntingtin modulate its sub-cellular localization, aggregation and effects on calcium homeostasis.

Vidya N. Nukala, J. Marsh, L. Thompson, 2007, Human molecular genetics.

Sirtuin 2 Inhibitors Rescue α-Synuclein-Mediated Toxicity in Models of Parkinson's Disease

Ruben Abagyan, Irina Kufareva, Bradley T. Hyman, 2007, Science.

Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases.

A. Young, B. Hyman, D. Housman, 2006, Proceedings of the National Academy of Sciences of the United States of America.

The Sirtuin-2 Inhibitor AK7 Is Neuroprotective in Models of Parkinson’s Disease but Not Amyotrophic Lateral Sclerosis and Cerebral Ischemia

C. Ayata, S. Moniot, C. Steegborn, 2015, PloS one.

The Sirtuin 2 microtubule deacetylase is an abundant neuronal protein that accumulates in the aging CNS.

Elizabeth M. Tomkinson, S. Hersch, A. Kazantsev, 2011, Human molecular genetics.

Evidence for a recruitment and sequestration mechanism in Huntington's disease.

D. Housman, A. Kazantsev, E. Preisinger, 1999, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

Sirtuins in Alzheimer’s Disease: SIRT2-Related GenoPhenotypes and Implications for PharmacoEpiGenetics

D. Goldgaber, R. Cacabelos, A. Kazantsev, 2019, International journal of molecular sciences.

Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease

D. Housman, J. Lecerf, J. Huston, 2001, Proceedings of the National Academy of Sciences of the United States of America.

A brain-permeable small molecule reduces neuronal cholesterol by inhibiting activity of sirtuin 2 deacetylase.

G. Bates, David M. Taylor, B. Woodman, 2011, ACS chemical biology.

SIRT2- and NRF2-Targeting Thiazole-Containing Compound with Therapeutic Activity in Huntington's Disease Models

R. Abagyan, J. Marsh, J. Landers, 2016 .

SIRT 2-and NRF 2-Targeting Thiazole-Containing Compound with Therapeutic Activity in Huntington ’ s Disease Models Highlights

R. Abagyan, J. Marsh, J. Landers, 2016 .

Editorial on Special Topic: Sirtuins in Metabolism, Aging, and Disease

T. Outeiro, A. Kazantsev, 2012, Front. Pharmacol..

Inhibition of Sirtuin 2 with Sulfobenzoic Acid Derivative AK1 is Non-Toxic and Potentially Neuroprotective in a Mouse Model of Frontotemporal Dementia

G. Carlson, Rose Pitstick, T. Spires-Jones, 2012, Front. Pharmacol..

LBH589, A Hydroxamic Acid-Derived HDAC Inhibitor, is Neuroprotective in Mouse Models of Huntington’s Disease

A. Young, S. Hersch, A. Kazantsev, 2016, Journal of Huntington's disease.

Identification of Tri‐ and Tetracyclic Pyrimidinediones as Sirtuin Inhibitors

M. Fraga, M. Esteller, L. Altucci, 2010, ChemMedChem.

Study of 1,4-dihydropyridine structural scaffold: discovery of novel sirtuin activators and inhibitors.

L. Altucci, A. Mai, A. Nebbioso, 2009, Journal of medicinal chemistry.

Two Approaches to Drug Discovery in SOD1-Mediated ALS

Robert H. Brown, M. Glicksman, A. Kazantsev, 2006, Journal of biomolecular screening.

SAR and QSAR study on 2-aminothiazole derivatives, modulators of transcriptional repression in Huntington's disease.

M. Sturlese, S. Moro, D. Rigamonti, 2008, Bioorganic & medicinal chemistry.

SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesis

Christian Neri, Emmanuel Lambert, Leslie M. Thompson, 2010, Proceedings of the National Academy of Sciences.

Biological and Potential Therapeutic Roles of Sirtuin Deacetylases

A. Kazantsev, R. Luthi-Carter, D. Taylor, 2008, Cellular and Molecular Life Sciences.

RNA interference-mediated silencing of mutant superoxide dismutase rescues cyclosporin A-induced death in cultured neuroblastoma cells.

Robert H. Brown, A. Kazantsev, P. Pasinelli, 2004, Proceedings of the National Academy of Sciences of the United States of America.

Therapeutic role of sirtuins in neurodegenerative disease.

T. Outeiro, A. Kazantsev, O. Marques, 2008, Biochimica et biophysica acta.

Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options

J. Lucas, K. Frey, B. Landwehrmeyer, 2009, European journal of neurology.

Mutant huntingtin alters MAPK signaling pathways in PC12 and striatal cells: ERK1/2 protects against mutant huntingtin-associated toxicity.

Katalin Illes, Leslie Michels Thompson, James M Olson, 2006, Human molecular genetics.

Autophagy regulates the processing of amino terminal huntingtin fragments.

L. Thompson, Z. Qin, N. Aronin, 2003, Human molecular genetics.

The role of Nrf2 signaling in counteracting neurodegenerative diseases

A. Dinkova-Kostova, A. Kazantsev, Rumen V. Kostov, 2018, The FEBS journal.

Insoluble detergent-resistant aggregates form between pathological and nonpathological lengths of polyglutamine in mammalian cells.

D. Housman, D. Goldgaber, A. Kazantsev, 1999, Proceedings of the National Academy of Sciences of the United States of America.

Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease.

R. Abagyan, A. Young, B. Hyman, 2007, Science.

Cystamine increases l‐cysteine levels in Huntington's disease transgenic mouse brain and in a PC12 model of polyglutamine aggregation

S. Hersch, R. Ferrante, A. Kazantsev, 2004, Journal of neurochemistry.

The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription.

D. Housman, E. Wanker, G. Bates, 2000, Proceedings of the National Academy of Sciences of the United States of America.

Pharmacological inhibition of PARP-1 reduces alpha-synuclein- and MPP+-induced cytotoxicity in Parkinson's disease in vitro models.

B. Hyman, D. Standaert, T. Outeiro, 2007, Biochemical and biophysical research communications.

Loss of Huntingtin Function Complemented by Small Molecules Acting as Repressor Element 1/Neuron Restrictive Silencer Element Silencer Modulators*

D. Bolognini, F. Sola, D. Rigamonti, 2007, Journal of Biological Chemistry.

KEAP1-modifying small molecule reveals muted NRF2 signaling responses in neural stem cells from Huntington's disease patients

S. Hersch, S. Tabrizi, B. Leavitt, 2017, Proceedings of the National Academy of Sciences.

Antisense-mediated down-regulation of the human huntingtin gene.

L. Thompson, W. Pardridge, A. Kazantsev, 2000, The Journal of pharmacology and experimental therapeutics.

Novel 7‐secretase inhibitors uncover a common nucleotide‐binding site in JAK3, SIRT2, and PS1

David M. Taylor, C. Schweizer, A. Kazantsev, 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

A small-molecule therapeutic lead for Huntington's disease: Preclinical pharmacology and efficacy of C2-8 in the R6/2 transgenic mouse

A. Young, D. Housman, S. Hersch, 2007, Proceedings of the National Academy of Sciences.

SIRT2 as a Therapeutic Target for Age-Related Disorders

R. M. de Oliveira, T. Outeiro, A. Kazantsev, 2012, Front. Pharmacol..

A bivalent Huntingtin binding peptide suppresses polyglutamine aggregation and pathogenesis in Drosophila

D. Housman, J. Marsh, L. Thompson, 2002, Nature Genetics.

The sirtuin 2 inhibitor AK-7 is neuroprotective in Huntington's disease mouse models.

S. Hersch, R. Ferrante, Jinho Kim, 2012, Cell reports.

Central role of alpha-synuclein oligomers in neurodegeneration in Parkinson disease.

A. Kazantsev, A. Kolchinsky, 2008, Archives of neurology.

University of Dundee The role of Nrf 2 signaling in counteracting neurodegenerative diseases

A. Dinkova-Kostova, A. Kazantsev, Rumen V. Kostov, 2018 .

Drug Targeting of α-Synuclein Oligomerization in Synucleinopathies

T. Outeiro, A. Kazantsev, 2008, Perspectives in medicinal chemistry.

Developing a neuroprotective therapy for Parkinson’s and Huntington’s diseases

A. Kazantsev, 2007 .

A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo.

A. Young, D. Housman, E. Wanker, 2005, Proceedings of the National Academy of Sciences of the United States of America.

Drug targeting of dysregulated transcription in Huntington's disease

S. Hersch, A. Kazantsev, 2007, Progress in Neurobiology.

Activation of Nrf2 signaling as a common treatment of neurodegenerative diseases.

A. Dinkova-Kostova, A. Kazantsev, 2017, Neurodegenerative disease management.

University of Dundee Activation of Nrf2 signaling as a common treatment of neurodegenerative diseases

A. Dinkova-Kostova, A. Kazantsev, 2017 .

Evaluation of Histone Deacetylases as Drug Targets in Huntington’s Disease models

S. Hersch, L. Altucci, A. Mai, 2010, PLoS currents.

Discovery of a Novel Small-Molecule Targeting Selective Clearance of Mutant Huntingtin Fragments

A. Young, D. Housman, Z. Hollingsworth, 2007, Journal of biomolecular screening.

Development and characterization of 3-(benzylsulfonamido)benzamides as potent and selective SIRT2 inhibitors.

M. Khanfar, A. Kazantsev, R. Silverman, 2014, European journal of medicinal chemistry.

SIRT2- and NRF2-Targeting Thiazole-Containing Compound with Therapeutic Activity in Huntington's Disease Models.

R. Abagyan, J. Marsh, J. Landers, 2016, Cell chemical biology.

Histone deacetylase inhibitors and neurodegenerative disorders: holding the promise.

A. Mai, D. Rotili, S. Valente, 2009, Current pharmaceutical design.

Discovery of bioactive small-molecule inhibitor of poly adp-ribose polymerase: implications for energy-deficient cells.

R. Abagyan, M. MacDonald, A. Young, 2006, Chemistry & biology.

New Directions for Neurodegenerative Disease Therapy: Using Chemical Compounds to Boost the Formation of Mutant Protein Inclusions

D. Housman, A. Kazantsev, R. Bodner, 2006, Cell cycle.

Putative human blue-light photoreceptors hCRY1 and hCRY2 are flavoproteins.

D. S. Hsu, Shaying Zhao, T. Todo, 1996, Biochemistry.

Huntington's disease: From molecular basis to therapeutic advances.

S. Krobitsch, A. Kazantsev, 2011, The international journal of biochemistry & cell biology.

Central Role of-Synuclein Oligomers in Neurodegeneration in Parkinson Disease

A. Kazantsev, A. Kolchinsky, 2008 .

A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo.

A. Young, D. Housman, E. Wanker, 2005, Proceedings of the National Academy of Sciences of the United States of America.

Drug Targeting of α-Synuclein Oligomerization in Synucleinopathies

D. Manallack, T. Outeiro, A. Kazantsev, 2007 .

Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options

J. Lucas, K. Frey, B. Landwehrmeyer, 2009, European journal of neurology.

KEAP1-modifying small molecule reveals muted NRF2 signaling responses in neural stem cells from Huntington's disease patients

S. Hersch, S. Tabrizi, B. Leavitt, 2017, Proceedings of the National Academy of Sciences.

Arfaptin 2 regulates the aggregation of mutant huntingtin protein

P. Peters, G. Bates, L. Thompson, 2002, Nature Cell Biology.

Autophagy regulates the processing of amino terminal huntingtin fragments.

L. Thompson, N. Aronin, A. Kazantsev, 2003, Human molecular genetics.

Development and characterization of 3-(benzylsulfonamido)benzamides as potent and selective SIRT2 inhibitors.

M. Khanfar, A. Kazantsev, R. Silverman, 2014, European journal of medicinal chemistry.

3-(N-arylsulfamoyl)benzamides, inhibitors of human sirtuin type 2 (SIRT2).

A. Kazantsev, R. Silverman, L. Quinti, 2012, Bioorganic & medicinal chemistry letters.

Substrate spectrum of human excinuclease: repair of abasic sites, methylated bases, mismatches, and bulky adducts.

D. S. Hsu, A. Sancar, A. Kazantsev, 1994, Proceedings of the National Academy of Sciences of the United States of America.